Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system
Purpose Silent corticotroph adenomas (SCAs) can be redefined according to the 2017 World Health Organization pituitary classification system with the introduction of T‑PIT, a transcription factor. We studied the clinical features of these redefined SCAs. Methods We compared 112 patients with SCAs an...
Gespeichert in:
| Veröffentlicht in: | Pituitary 2021-08, Vol.24 (4), p.564-573 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 573 |
|---|---|
| container_issue | 4 |
| container_start_page | 564 |
| container_title | Pituitary |
| container_volume | 24 |
| creator | Jiang, Shenzhong Zhu, Jianyu Feng, Ming Yao, Yong Deng, Kan Xing, Bing Lian, Wei Wang, Renzhi Bao, Xinjie |
| description | Purpose
Silent corticotroph adenomas (SCAs) can be redefined according to the 2017 World Health Organization pituitary classification system with the introduction of T‑PIT, a transcription factor. We studied the clinical features of these redefined SCAs.
Methods
We compared 112 patients with SCAs and 198 patients with silent gonadotroph adenomas (SGAs) who underwent surgery from January 2019 to May 2020.
Results
The prevalence of SCAs increased from 21.3 to 30.2% under the new classification rules. T-PIT-positive, adrenocorticotropic hormone-negative SCAs and T-PIT-positive, adrenocorticotropic hormone-positive SCAs exhibited similar clinical features. SCAs exhibited significant female preponderance (90.2% vs. 29.8%,
P
|
| doi_str_mv | 10.1007/s11102-021-01133-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2549836587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2549836587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-bd0e02233071b537ed1fd95a6bad7f4fca84c8cbfb3e336195c613a2b7a014973</originalsourceid><addsrcrecordid>eNp9kctOwzAQRS0Eorx-gAWyxDrgySR1ukQVUCQkNiDYWY5jt66SONiuUL-E38WlPCQWrDy2z9x5XEJOgV0AY_wyAADLM5ZDxgAQs2qHHEDJMeMFw90UYzXOsICXETkMYclYSsNin4wQxyUgVAfkfdra3irZ0sE7Y1sdqDM0pKCPVDkfrXLRu2FBZaN718mQXrtBet3QNxsX3-jc9bL5S0oTtU9XN0Tbz2lcaJoz4PR59kAHG1c2Sr-mqpUhWJOaiNb1NKxD1N0x2TOyDfrk6zwiTzfXj9NZdv9weze9us8U8jJmdcM0y3NExqEukesGTDMp5biWDTeFUbIqVKVqU6NOQ8OkVGNAmddcMigmHI_I-VY3jf-60iGKpVv5PpUUeVlMqrSoakPlW0p5F4LXRgzedql5AUxsvBBbL0TyQnx6IaqUdPYlvao73fykfC8_AbgFQvrq59r_1v5H9gOWCJe0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2549836587</pqid></control><display><type>article</type><title>Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system</title><source>SpringerLink Journals</source><creator>Jiang, Shenzhong ; Zhu, Jianyu ; Feng, Ming ; Yao, Yong ; Deng, Kan ; Xing, Bing ; Lian, Wei ; Wang, Renzhi ; Bao, Xinjie</creator><creatorcontrib>Jiang, Shenzhong ; Zhu, Jianyu ; Feng, Ming ; Yao, Yong ; Deng, Kan ; Xing, Bing ; Lian, Wei ; Wang, Renzhi ; Bao, Xinjie</creatorcontrib><description>Purpose
Silent corticotroph adenomas (SCAs) can be redefined according to the 2017 World Health Organization pituitary classification system with the introduction of T‑PIT, a transcription factor. We studied the clinical features of these redefined SCAs.
Methods
We compared 112 patients with SCAs and 198 patients with silent gonadotroph adenomas (SGAs) who underwent surgery from January 2019 to May 2020.
Results
The prevalence of SCAs increased from 21.3 to 30.2% under the new classification rules. T-PIT-positive, adrenocorticotropic hormone-negative SCAs and T-PIT-positive, adrenocorticotropic hormone-positive SCAs exhibited similar clinical features. SCAs exhibited significant female preponderance (90.2% vs. 29.8%,
P
< 0.0001); more frequent invasion (36.6% vs. 7.6%,
P
< 0.0001), especially multiple-site invasion (
P
< 0.0001); and marked cystic changes on imaging compared with SGAs (54.5% vs. 19.2%,
P
< 0.0001). SCAs had a softer tumor consistency (89.2% vs. 61.1%,
P
< 0.0001). Gross total resection was achieved in 66.1% of SCAs and 66.2% of SGAs (
P
> 0.9999). The overall recurrence/progression rates of SCAs and SGAs were 9.8% and 6.6% at 14.1 and 13.5 months of follow-up, respectively (
P
= 0.3765). The proportion of patients with more than two recurrences requiring multiple surgeries and radiation was similar between SCAs and SGAs (7.1% vs. 3.0%,
P
= 0.1514). However, multiple recurrences of SCAs affected younger patients than SGAs (39.0 vs. 53.5 years,
P
= 0.0433).
Conclusions
The prevalence of SCAs increased with the introduction of T-PIT. SCAs and SGAs exhibited comparable size and recurrence/progression rates, but SCAs showed increased invasion and more marked cystic change. Aggressive SCAs tended to affect younger patients. Close long-term monitoring for SCA recurrence/progression is required.</description><identifier>ISSN: 1386-341X</identifier><identifier>EISSN: 1573-7403</identifier><identifier>DOI: 10.1007/s11102-021-01133-8</identifier><identifier>PMID: 33651318</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adrenocorticotropic hormone ; Classification ; Endocrinology ; Human Physiology ; Medicine ; Medicine & Public Health ; Patients ; Pituitary ; Pituitary (anterior) ; Surgery ; Tumors</subject><ispartof>Pituitary, 2021-08, Vol.24 (4), p.564-573</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-bd0e02233071b537ed1fd95a6bad7f4fca84c8cbfb3e336195c613a2b7a014973</citedby><cites>FETCH-LOGICAL-c375t-bd0e02233071b537ed1fd95a6bad7f4fca84c8cbfb3e336195c613a2b7a014973</cites><orcidid>0000-0003-2117-7692</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11102-021-01133-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11102-021-01133-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33651318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Shenzhong</creatorcontrib><creatorcontrib>Zhu, Jianyu</creatorcontrib><creatorcontrib>Feng, Ming</creatorcontrib><creatorcontrib>Yao, Yong</creatorcontrib><creatorcontrib>Deng, Kan</creatorcontrib><creatorcontrib>Xing, Bing</creatorcontrib><creatorcontrib>Lian, Wei</creatorcontrib><creatorcontrib>Wang, Renzhi</creatorcontrib><creatorcontrib>Bao, Xinjie</creatorcontrib><title>Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system</title><title>Pituitary</title><addtitle>Pituitary</addtitle><addtitle>Pituitary</addtitle><description>Purpose
Silent corticotroph adenomas (SCAs) can be redefined according to the 2017 World Health Organization pituitary classification system with the introduction of T‑PIT, a transcription factor. We studied the clinical features of these redefined SCAs.
Methods
We compared 112 patients with SCAs and 198 patients with silent gonadotroph adenomas (SGAs) who underwent surgery from January 2019 to May 2020.
Results
The prevalence of SCAs increased from 21.3 to 30.2% under the new classification rules. T-PIT-positive, adrenocorticotropic hormone-negative SCAs and T-PIT-positive, adrenocorticotropic hormone-positive SCAs exhibited similar clinical features. SCAs exhibited significant female preponderance (90.2% vs. 29.8%,
P
< 0.0001); more frequent invasion (36.6% vs. 7.6%,
P
< 0.0001), especially multiple-site invasion (
P
< 0.0001); and marked cystic changes on imaging compared with SGAs (54.5% vs. 19.2%,
P
< 0.0001). SCAs had a softer tumor consistency (89.2% vs. 61.1%,
P
< 0.0001). Gross total resection was achieved in 66.1% of SCAs and 66.2% of SGAs (
P
> 0.9999). The overall recurrence/progression rates of SCAs and SGAs were 9.8% and 6.6% at 14.1 and 13.5 months of follow-up, respectively (
P
= 0.3765). The proportion of patients with more than two recurrences requiring multiple surgeries and radiation was similar between SCAs and SGAs (7.1% vs. 3.0%,
P
= 0.1514). However, multiple recurrences of SCAs affected younger patients than SGAs (39.0 vs. 53.5 years,
P
= 0.0433).
Conclusions
The prevalence of SCAs increased with the introduction of T-PIT. SCAs and SGAs exhibited comparable size and recurrence/progression rates, but SCAs showed increased invasion and more marked cystic change. Aggressive SCAs tended to affect younger patients. Close long-term monitoring for SCA recurrence/progression is required.</description><subject>Adrenocorticotropic hormone</subject><subject>Classification</subject><subject>Endocrinology</subject><subject>Human Physiology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Patients</subject><subject>Pituitary</subject><subject>Pituitary (anterior)</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1386-341X</issn><issn>1573-7403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kctOwzAQRS0Eorx-gAWyxDrgySR1ukQVUCQkNiDYWY5jt66SONiuUL-E38WlPCQWrDy2z9x5XEJOgV0AY_wyAADLM5ZDxgAQs2qHHEDJMeMFw90UYzXOsICXETkMYclYSsNin4wQxyUgVAfkfdra3irZ0sE7Y1sdqDM0pKCPVDkfrXLRu2FBZaN718mQXrtBet3QNxsX3-jc9bL5S0oTtU9XN0Tbz2lcaJoz4PR59kAHG1c2Sr-mqpUhWJOaiNb1NKxD1N0x2TOyDfrk6zwiTzfXj9NZdv9weze9us8U8jJmdcM0y3NExqEukesGTDMp5biWDTeFUbIqVKVqU6NOQ8OkVGNAmddcMigmHI_I-VY3jf-60iGKpVv5PpUUeVlMqrSoakPlW0p5F4LXRgzedql5AUxsvBBbL0TyQnx6IaqUdPYlvao73fykfC8_AbgFQvrq59r_1v5H9gOWCJe0</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Jiang, Shenzhong</creator><creator>Zhu, Jianyu</creator><creator>Feng, Ming</creator><creator>Yao, Yong</creator><creator>Deng, Kan</creator><creator>Xing, Bing</creator><creator>Lian, Wei</creator><creator>Wang, Renzhi</creator><creator>Bao, Xinjie</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><orcidid>https://orcid.org/0000-0003-2117-7692</orcidid></search><sort><creationdate>20210801</creationdate><title>Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system</title><author>Jiang, Shenzhong ; Zhu, Jianyu ; Feng, Ming ; Yao, Yong ; Deng, Kan ; Xing, Bing ; Lian, Wei ; Wang, Renzhi ; Bao, Xinjie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-bd0e02233071b537ed1fd95a6bad7f4fca84c8cbfb3e336195c613a2b7a014973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adrenocorticotropic hormone</topic><topic>Classification</topic><topic>Endocrinology</topic><topic>Human Physiology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Patients</topic><topic>Pituitary</topic><topic>Pituitary (anterior)</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Shenzhong</creatorcontrib><creatorcontrib>Zhu, Jianyu</creatorcontrib><creatorcontrib>Feng, Ming</creatorcontrib><creatorcontrib>Yao, Yong</creatorcontrib><creatorcontrib>Deng, Kan</creatorcontrib><creatorcontrib>Xing, Bing</creatorcontrib><creatorcontrib>Lian, Wei</creatorcontrib><creatorcontrib>Wang, Renzhi</creatorcontrib><creatorcontrib>Bao, Xinjie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Pituitary</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Shenzhong</au><au>Zhu, Jianyu</au><au>Feng, Ming</au><au>Yao, Yong</au><au>Deng, Kan</au><au>Xing, Bing</au><au>Lian, Wei</au><au>Wang, Renzhi</au><au>Bao, Xinjie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system</atitle><jtitle>Pituitary</jtitle><stitle>Pituitary</stitle><addtitle>Pituitary</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>24</volume><issue>4</issue><spage>564</spage><epage>573</epage><pages>564-573</pages><issn>1386-341X</issn><eissn>1573-7403</eissn><abstract>Purpose
Silent corticotroph adenomas (SCAs) can be redefined according to the 2017 World Health Organization pituitary classification system with the introduction of T‑PIT, a transcription factor. We studied the clinical features of these redefined SCAs.
Methods
We compared 112 patients with SCAs and 198 patients with silent gonadotroph adenomas (SGAs) who underwent surgery from January 2019 to May 2020.
Results
The prevalence of SCAs increased from 21.3 to 30.2% under the new classification rules. T-PIT-positive, adrenocorticotropic hormone-negative SCAs and T-PIT-positive, adrenocorticotropic hormone-positive SCAs exhibited similar clinical features. SCAs exhibited significant female preponderance (90.2% vs. 29.8%,
P
< 0.0001); more frequent invasion (36.6% vs. 7.6%,
P
< 0.0001), especially multiple-site invasion (
P
< 0.0001); and marked cystic changes on imaging compared with SGAs (54.5% vs. 19.2%,
P
< 0.0001). SCAs had a softer tumor consistency (89.2% vs. 61.1%,
P
< 0.0001). Gross total resection was achieved in 66.1% of SCAs and 66.2% of SGAs (
P
> 0.9999). The overall recurrence/progression rates of SCAs and SGAs were 9.8% and 6.6% at 14.1 and 13.5 months of follow-up, respectively (
P
= 0.3765). The proportion of patients with more than two recurrences requiring multiple surgeries and radiation was similar between SCAs and SGAs (7.1% vs. 3.0%,
P
= 0.1514). However, multiple recurrences of SCAs affected younger patients than SGAs (39.0 vs. 53.5 years,
P
= 0.0433).
Conclusions
The prevalence of SCAs increased with the introduction of T-PIT. SCAs and SGAs exhibited comparable size and recurrence/progression rates, but SCAs showed increased invasion and more marked cystic change. Aggressive SCAs tended to affect younger patients. Close long-term monitoring for SCA recurrence/progression is required.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33651318</pmid><doi>10.1007/s11102-021-01133-8</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2117-7692</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-341X |
| ispartof | Pituitary, 2021-08, Vol.24 (4), p.564-573 |
| issn | 1386-341X 1573-7403 |
| language | eng |
| recordid | cdi_proquest_journals_2549836587 |
| source | SpringerLink Journals |
| subjects | Adrenocorticotropic hormone Classification Endocrinology Human Physiology Medicine Medicine & Public Health Patients Pituitary Pituitary (anterior) Surgery Tumors |
| title | Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A01%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20profiles%20of%20silent%20corticotroph%20adenomas%20compared%20with%20silent%20gonadotroph%20adenomas%20after%20adopting%20the%202017%20WHO%20pituitary%20classification%20system&rft.jtitle=Pituitary&rft.au=Jiang,%20Shenzhong&rft.date=2021-08-01&rft.volume=24&rft.issue=4&rft.spage=564&rft.epage=573&rft.pages=564-573&rft.issn=1386-341X&rft.eissn=1573-7403&rft_id=info:doi/10.1007/s11102-021-01133-8&rft_dat=%3Cproquest_cross%3E2549836587%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2549836587&rft_id=info:pmid/33651318&rfr_iscdi=true |